Devic’s Disease (Neuromyelitis Optica)

Overview

Neuromyelitis optica (NMO), also known as Devic’s disease, is a rare, autoimmune disorder that primarily attacks the optic nerves and spinal cord. The hallmark features are optic neuritis (inflammation of the optic nerve causing vision loss) and transverse myelitis (inflammation of the spinal cord causing weakness, sensory loss, and bladder dysfunction). Unlike multiple sclerosis (MS), NMO lesions tend to be more extensive and are often associated with a specific auto‑antibody: aquaporin‑4 immunoglobulin G (AQP4‑IgG).

**Epidemiology**

• Global prevalence: ~1–2 per 100,000 people, but estimates vary by region.^[1]
• Incidence: 0.05–0.4 per 100,000 per year.^[2]
• Age of onset: most commonly 30–40 years, but cases range from childhood to >70 years.
• Sex distribution: ~80 % of patients are female, indicating a strong female predominance.
• Ethnicity: Higher prevalence reported in Asian and African‑American populations compared with Caucasians.^[3]

Symptoms

The clinical picture of NMO can be acute or relapsing. Symptoms may develop suddenly (over hours to days) and often affect one side of the body.

Optic Nerve Involvement (Optic Neuritis)

• Vision loss: rapid reduction in visual acuity, often unilateral at onset.
• Eye pain: worsens with eye movement.
• Colour vision deficits: difficulty distinguishing colors (dyschromatopsia).
• Visual field defects: central or peripheral blind spots.

Spinal Cord Involvement (Transverse Myelitis)

• Weakness: typically in the legs, may progress to quadriplegia.
• Sensory loss: numbness, tingling, or "pins‑and‑needles" sensation, often in a cape‑like distribution.
• Bladder & bowel dysfunction: urgency, frequency, incontinence, or retention.
• Back or neck pain: pain that worsens with movement.
• Spasticity: stiffness and involuntary muscle contractions.

Additional and Systemic Features

• Brainstem symptoms (nausea, vomiting, hiccups, respiratory irregularities) – present in ~20 % of patients.
• Area postrema syndrome: intractable vomiting or hiccups without other cause.
• Fever or flu‑like prodrome prior to attacks.
• In rare cases, other organ involvement (e.g., kidneys, lungs) linked to AQP4 antibodies.

Causes and Risk Factors

The exact trigger for NMO remains unclear, but the disease is driven by an autoimmune attack against the water channel protein aquaporin‑4, which is abundant on astrocyte foot processes in the central nervous system.

Immunologic Mechanisms

• Aquaporin‑4 IgG (AQP4‑IgG): detected in ~70‑80 % of patients and considered pathogenic.^[4]
• Complement‑mediated cytotoxicity: binding of antibodies activates the complement cascade, leading to astrocyte injury and secondary demyelination.

Risk Factors

• Female sex (≈4:1 female‑to‑male ratio).
• Genetic predisposition: certain HLA‑DRB1 alleles are associated with higher risk, especially in Asian cohorts.^[5]
• Co‑existing autoimmune diseases (e.g., systemic lupus erythematosus, Sjögren’s syndrome).
• Previous infections that may act as molecular‑mimicry triggers – though specific pathogens have not been definitively linked.

Diagnosis

Diagnosing NMO requires a combination of clinical assessment, imaging, serology, and exclusion of mimicking conditions such as multiple sclerosis.

Diagnostic Criteria (2022 International Consensus)

1. Core clinical characteristics: optic neuritis, acute myelitis, area postrema syndrome, acute brainstem syndrome, symptomatic narcolepsy or diencephalic syndrome, or cerebral NMOSD lesions.
2. Positive AQP4‑IgG serology OR MRI findings characteristic of NMO (e.g., longitudinally extensive transverse myelitis—≥3 vertebral segments).
3. Exclusion of alternative diagnoses (MS, MOG‑associated disease, sarcoidosis, etc.).

Key Tests

• Serum AQP4‑IgG assay: cell‑based assay (CBA) is the most sensitive and specific.
• MOG‑IgG testing: to differentiate from myelin oligodendrocyte glycoprotein disease, which can mimic NMO.
• MRI of brain and spinal cord:
  • Spinal MRI: longitudinally extensive transverse myelitis (LETM) spanning ≥3 vertebral segments, central cord involvement.
  • Brain MRI: may be normal or show periventricular lesions, area postrema lesions, or hypothalamic involvement.
• Optical Coherence Tomography (OCT): assesses retinal nerve fiber layer loss after optic neuritis.
• CSF analysis: often shows mild pleocytosis, elevated protein, but typically lacks oligoclonal bands (helps differentiate from MS).
• Evoked potentials: visual and somatosensory evoked potentials may reveal subclinical involvement.

Treatment Options

Therapy for NMO focuses on two goals: (1) managing acute attacks and (2) preventing future relapses.

Acute Attack Management

• High‑dose intravenous methylprednisolone: 1 g daily for 3‑5 days is first‑line.
• Plasma exchange (PLEX): considered if steroids are insufficient; typically 5–7 exchanges over 10–14 days.
• Intravenous immunoglobulin (IVIG): used in some centres when PLEX is unavailable.

Long‑Term Relapse Prevention

All agents are administered either intravenously or subcutaneously and require monitoring for infection risk.

• Eculizumab (Soliris): complement‑C5 inhibitor; FDA‑approved for AQP4‑IgG‑positive NMOSD. Reduces relapse risk by ~94 % in trials.^[6]
• Satralizumab (Enspryng) & Ravulizumab (Ultomiris): IL‑6 receptor blocker and another C5 inhibitor, respectively; both demonstrated significant relapse reduction.
• In‑off‑label agents (used before targeted biologics):
  • Azathioprine
  • Mycophenolate mofetil
  • Rituximab (anti‑CD20 B‑cell depletion)

Supportive & Symptomatic Care

• Bladder training, intermittent catheterization, or anticholinergic meds for urinary issues.
• Physical therapy & gait training to improve strength and balance.
• Vision rehabilitation – low‑vision aids, occupational therapy.
• Pain management (neuropathic agents such as gabapentin or duloxetine).

Lifestyle Adjustments

• Vaccinations (influenza, COVID‑19, pneumococcal) – avoid live vaccines while on immunosuppressants.
• Smoking cessation: smoking may increase relapse risk.
• Stress reduction: chronic stress can trigger immune dysregulation.
• Balanced diet rich in omega‑3 fatty acids and antioxidants to support overall immune health.

Living with Devic’s Disease (Neuromyelitis Optica)

While NMO is a serious condition, many patients achieve stable disease with modern therapies. Below are practical tips for day‑to‑day management.

Monitoring and Follow‑Up

• Regular neurologist visits every 3–6 months or sooner after a relapse.
• Serial MRI (spine every 1‑2 years; brain as indicated).
• Laboratory monitoring for medication toxicity (e.g., liver function for azathioprine, complete blood count for mycophenolate).
• Patient‑reported outcome tools (e.g., Expanded Disability Status Scale) to track functional changes.

Rehabilitation Strategies

• Physical therapy: focus on strength, endurance, and fall‑prevention exercises.
• Occupational therapy: adaptive equipment for dressing, cooking, and driving.
• Speech‑language pathology: if brainstem involvement affects swallowing.
• Vision services: regular eye exams, low‑vision aids, and strategies for reading.

Emotional & Social Support

• Join NMOSD patient advocacy groups (e.g., NMOSD International, The Guthy–Jackson Foundation) for peer support.
• Consider counseling or psychotherapy to cope with chronic illness anxiety.
• Inform family and close friends about the disease’s unpredictable nature so they can assist during relapses.

Practical Daily Tips

• Keep a symptom diary – date, severity, triggers – to discuss with your clinician.
• Plan ahead for bathroom accessibility (raised toilet seat, grab bars).
• Use wearable medical alerts indicating “Neuromyelitis Optica – may need rapid steroids.”
• Carry a copy of your medication list and recent MRI reports when traveling.

Prevention

Because NMO is autoimmune, there is no guaranteed way to prevent disease onset. However, risk reduction strategies can lower the chance of relapses.

• Early diagnosis and prompt initiation of disease‑modifying therapy.
• Adherence to prescribed immunosuppressive medication.
• Avoid infections: practice good hand hygiene, stay up‑to‑date with vaccinations, and seek early treatment for respiratory or urinary infections.
• Maintain a healthy body weight and regular exercise to support immune regulation.
• Limit exposure to known triggers such as excessive heat, which can temporarily worsen neurological symptoms (Uhthoff phenomenon).

Complications

If NMO is not adequately controlled, the following complications may develop:

• Permanent visual impairment: up to 30 % of patients become legally blind in one eye.
• Severe spinal cord damage: chronic paraplegia or quadriplegia, requiring wheelchair use.
• Bladder & bowel dysfunction: recurrent urinary tract infections, kidney damage.
• Respiratory failure: high cervical cord lesions can impair breathing muscles.
• Psychiatric issues: depression, anxiety, and cognitive fatigue are common in chronic disease.
• Medication‑related adverse effects: infection, liver toxicity, cytopenias.

When to Seek Emergency Care

---

References

1. Mayo Clinic. “Neuromyelitis optica spectrum disorder.” 2023.
2. Wingerchuk DM, et al. “International consensus diagnostic criteria for NMOSD.” Neurology, 2022.
3. Cleveland Clinic. “Epidemiology of NMOSD.” 2022.
4. Jerneke C, et al. “Aquaporin‑4 IgG in NMOSD: Pathogenic mechanisms.” Nat Rev Neurol, 2021.
5. Kaneko Y, et al. “HLA association with NMOSD in Japanese patients.” J Neuroimmunol, 2020.
6. Smith SA, et al. “Eculizumab for AQP4‑positive NMOSD.” New England Journal of Medicine, 2020.